Prosecution Insights
Last updated: April 19, 2026

Novartis Pharma AG

4 pending office actions

Portfolio Summary

4
Total Pending OAs
0
Final Rejections
4
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18271186 OXALAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY FETTEROLF, BRANDON J 1626 Non-Final OA Jul 06, 2023
18266199 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY BURKETT, DANIEL JOHN 1624 Non-Final OA Jun 08, 2023
17925166 SUBSTITUTED PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF SZNAIDMAN, MARCOS L 1628 Non-Final OA Nov 14, 2022
17376829 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY SHTERENGARTS, SAMANTHA L 1623 Non-Final OA Jul 15, 2021

Managing Novartis Pharma AG's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month